Jazz Pharmaceuticals and Zymeworks Announce Exclusive License Agreement to Develop and Commercialize Zanidatamab, a HER2-Targeted Bispecific Antibody
Stock Information for Zymeworks Inc.
Loading
Please wait while we load your information from QuoteMedia.